CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences to Participate in Upcoming Investor Conferences

20 ноя 2024 16:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update

06 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

25 сен 2024 09:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

03 сен 2024 08:01:11 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

26 авг 2024 16:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

12 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

06 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

09 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

02 июн 2024 19:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

30 май 2024 16:01:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

07 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 10:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 апр 2024 09:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

04 апр 2024 16:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

05 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

15 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

07 янв 2024 11:00:00 Источник Nasdaq GlobeNewswire

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

12 дек 2023 16:02:00 Источник Nasdaq GlobeNewswire